Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731002 · ClinicalTrials.gov registry record · Phase 2
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT01731002 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 224 participants.
The verdict
NCT01731002, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
Interventions
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Latanoprost ophthalmic solution 0.005%
- DRUG AR-13324 Ophthalmic Solution 0.01%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01731002
The ClinicalTrials.gov registry entry for NCT01731002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which AR-13324 Ophthalmic Solution 0.02% is the first listed.
NCT01731002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01731002 about?
NCT01731002 is a clinical study titled "Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure". Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
What is the current status of trial NCT01731002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2012-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01731002?
The interventions under investigation include: AR-13324 Ophthalmic Solution 0.02% (DRUG), Latanoprost ophthalmic solution 0.005% (DRUG), AR-13324 Ophthalmic Solution 0.01% (DRUG).
Who is sponsoring clinical trial NCT01731002?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.